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Abstract
Background: Maternal depression can be harmful to both mothers and their children. Omega-3 polyunsaturated
fatty acid (PUFA) supplementation has been investigated as an alternative intervention for pregnant women with
depressive symptoms because of the supporting evidence from clinical trials in major depression, the safety
advantage, and its anti-inflammatory and neuroplasticity effects. This study examines the efficacy of omega-3 PUFA
supplementation for pregnant women with depressive symptoms in Taiwan and Japan, to provide evidence
available for Asia. The rationale and protocol of this trial are reported here.
Methods: The Synchronized Trial on Expectant Mothers with Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)
is a multicenter, double-blind, parallel group, randomized controlled trial. Participants will be randomized to either
the omega-3 PUFAs arm (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily) or placebo arm.
Primary outcome is total score on the Hamilton Rating Scale for Depression (HAMD) at 12 weeks after the start of
the intervention. We will randomize 56 participants to have 90 % power to detect a 4.7-point difference in mean
HAMD scores with omega-3 PUFAs compared with placebo. Because seafood consumption varies across countries
and this may have a major effect on the efficacy of omega-3 PUFA supplementation, 56 participants will be
recruited at each site in Taiwan and Japan, for a total number of 112 participants. Secondary outcomes include
depressive symptoms at 1 month after childbirth, diagnosis of major depressive disorder, changes in omega-3
PUFAs concentrations and levels of biomarkers at baseline and at 12 weeks’ follow-up, and standard obstetric
outcomes. Data analyses will be by intention to treat. The trial was started in June 2014 and is scheduled to end in
February 2018.
Discussion: The trial is expected to provide evidence that can contribute to promoting mental health among
mothers and children in Asian populations.
Trial registration: Clinicaltrials.gov: NCT02166424. Registered 15 June 2014; University Hospital Medical Information
Network (UMIN) Center: UMIN000017979. Registered 20 May 2015.
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Background
A systematic review reported the prevalence of depres-
sion during pregnancy was 7.4 % for the first trimester,
12.8 % for the second, and 12.0 % for the third [1]. A
meta-analysis estimated the prevalence of major and
minor depression in the range of 6.5 to 12.9 % during
the different trimesters of pregnancy and during the first
12 months postpartum [2]. Depression during pregnancy
can have harmful effects on both the mother and child.
The mother may experience difficulties performing daily
activities, fail to seek prenatal care, have a poor diet, use
tobacco, alcohol, or other harmful substances, and be at
risk of self-harm or suicide [3]; fetal growth rate may be
slower; and the child may have temperament or behav-
ioral problems later [4–6].
The established treatment options for depression in-
clude antidepressants, cognitive behavioral therapy
(CBT), and interpersonal psychotherapy (IPT). However,
there are some limitations to each of these options. In
terms of antidepressants, guidelines recommend all anti-
depressant drugs be used with caution during pregnancy
and that selective serotonin reuptake inhibitors such as
paroxetine be avoided [7, 8]. In fact, it was found in a
population screening study of pregnant women attend-
ing antenatal clinics that only 11 % of pregnant women
with major depressive disorders (MDD) were actually re-
ceiving suitable antidepressant medication [9]. Both CBT
and IPT are recommended for pregnant women with
mild or moderate depression [10] and an RCT has
shown that IPT was effective for depression during preg-
nancy [11], but pregnant women cannot always access
CBT or IPT. Identifying a safe alternative treatment
strategy for depression during pregnancy is therefore
desirable.
Many meta-analyses of RCTs [12–19], although not all
[20, 21], support the positive effects of omega-3 polyun-
saturated fatty acid (omega-3 PUFA) supplementation
on depressive symptoms. The latest evidence supports
the efficacy of omega-3 PUFAs rich in eicosapentaenoic
acid (EPA) against depression [14, 16–18].
Omega-3 PUFAs are essential nutrients for maintain-
ing physiological function of the mothers and infants
during pregnancy. A previous study showed that omega-
3 PUFA content in the brain of pregnant rats can be re-
duced after a single reproductive cycle when they are de-
prived of sufficient dietary omega-3 PUFAs, a reduction
which may affect neuronal function [22]. In addition, an-
other study reported that the brain decreases in volume
in pregnant women [23]. It has been suggested that
changes in the phospholipid content of the brain’s mem-
branes could reduce brain size [24]. It is known that the
composition of maternal phospholipid membranes can
be altered during pregnancy by the fetus scavenging es-
sential fatty acids such as omega-3 PUFAs, and this
could potentially change brain morphology [23]. A lack
of omega-3 PUFAs, then, may have a harmful effect on
maternal mental health as well as on neurodevelopment
of the fetus and infant. A naturalistic longitudinal study
showed that lower seafood intake in pregnant women
was associated with an increased risk of their children
having suboptimum neurodevelopment [25]. To date, al-
though two RCTs have failed to show the efficacy of
omega-3 PUFAs for pregnant women with depression
[26, 27], the supplements used contained high levels of
docosahexaenoic acid (DHA) rather than EPA.
In a previous RCT conducted in Taiwan, our group
showed the efficacy of supplements with a high ratio of
EPA (2.2 g daily) to DHA (1.2 g daily) for depression in
pregnancy [28]. However, it is not yet clear what the ap-
propriate amount of supplemental omega-3 PUFAs is
and it may differ between countries because of national
differences in the consumption of fish, which is a rich
source of omega-3 PUFAs. Although fish consumption
in Taiwan is higher than in most Western countries, it is
half that in Japan [29]. The recommended daily intake
for pregnant women in Japan is 1.8 g of omega-3 PUFAs
[30], and the usual dose of pure EPA as a prescription
drug is also set at 1.8 g daily.
Recently, we suggested the potential efficacy of moder-
ate amount of omega-3 PUFAs supplementation for im-
proving depressive symptoms in our open label trial
conducted in Japan and Taiwan [31]. The objective of
the present randomized controlled trial is to determine
the efficacy of a daily dose of 1.8 g of omega-3 PUFAs
supplements (1.2 g EPA and 0.6 g DHA) for depressive
symptoms in pregnant women in Japan and Taiwan.
Examining the efficacy and safety of 1.8 g of omega-3
PUFAs supplementation in different countries is clinic-
ally relevant because not only is fish consumption gener-
ally higher and the prevalence of depression generally
lower in East Asian countries such as Japan and Taiwan
compared with Western countries, but also there are
considerable differences between East Asian countries
[29]. The study is called the Synchronized Trial on
Expectant Mothers with Depressive Symptoms by
Omega-3 PUFAs (SYNCHRO), and this paper explains
the rationale and describes protocol of the trial. An
additional file provides the completed SPIRIT 2013
Checklist (see Additional file 1).
Methods/Design
SYNCHRO is a multicenter, double-blind, parallel group,
randomized controlled trial that will allocate participants
to an intervention arm to receive omega-3 fatty acid
supplementation or a parallel placebo arm in the ratio of
1:1. The trial will run from June 2014 through February
2018, with participant enrollment between June 2014
and August 2017.
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The study was registered at clinicaltrials.gov (NCT0
2166424) on June 15, 2014 and the University Hospital
Medical Information Network (UMIN) Center (UMIN0
00017979) on June 22, 2015.
Inclusion criteria
Pregnant women who are between 12 and 24 weeks of
gestation will be recruited and followed through their
pregnancy and up to 4 weeks after childbirth. The inclu-
sion criteria are:
1) Pregnant and aged ≥20 years
2) Japanese conversational ability at the Japan site or
Chinese conversational ability at the Taiwan site to
ensure participants have sufficient understanding of the
trial’s scope and can provide written informed consent
3) Planning to remain in the Tokyo area or Taichung
area for 4–6 weeks after childbirth
4) Edinburgh Postnatal Depression Scale (EPDS) score
of ≥9
5) In good physical health as judged by an obstetrician
Exclusion criteria
The presence of any of the following will result in exclu-
sion from the trial.
1) History or current suspicion of psychosis, bipolar I
disorder, substance abuse or related disorder, eating
disorder, or personality disorder
2) Serious psychiatric symptoms, such as self-harm
behavior, or in need of rapid psychiatric treatment
3) Normal birth not expected (e.g., fetal malformation)
4) History of bleeding disorder such as von
Willebrand’s Disease
5) Regular treatment with aspirin or warfarin for the
past 3 months
6) Smoking habit of ≥40 cigarettes per day
7) Regular treatment with ethyl icosapentate or regular
consumption of omega-3 PUFA supplements for the
past 3 months
8) Habit of eating fish as a main dish ≥4 times per week
Procedure
Eligible patients will be screened using the EPDS at
three locations in cooperation with obstetricians: Toda
Chuo Women’s Hospital and the National Center for
Child Health and Development, both in Japan, and
China Medical University Hospital, Taiwan. Toda Chuo
Women’s Hospital is a local base hospital, and the
National Center for Child Health and Development and
China Medical University Hospital are academic hospi-
tals. Clinical research coordinators, who will be well-
trained nurses, psychologists or psychiatrists, will invite
eligible patients to take part in the study. Patients will
receive a comprehensive obstetric examination before
the study commences and undergo a baseline assess-
ment before randomization. Figure 1 shows a flow dia-
gram of the study protocol.
Randomization
Central registration involved assigning participants to
each group according to an assignment diagram that
was developed by a statistician. Using a computer-
generated random allocation sequence, they created
block randomization tables with two stratification fac-
tors: diagnosis of current MDD and study site. The test
will be double-blinded and only after all participants
have completed the protocol and all the results have
been tabulated will the research term be informed of the
results of the randomization. Stratification was justified
by previous studies: the results of a meta-analysis
showed some evidence supporting the benefits of
omega-3 PUFAs in individuals diagnosed with MDD but
no evidence supporting any benefits in individuals with-
out MDD [32]. Moreover, a previous study showed that
seafood consumption predicted prevalence rates of post-
partum depression across countries [33].
Intervention
Participants will take omega-3 PUFAs capsules or placebo
capsules for 12 weeks, and can take an entire day’s dosage
at once or spread throughout the day. The omega-3
PUFAs capsules have been formulated to each contain
134 mg of EPA and 67.7 mg of DHA, and a total of 9 cap-
sules containing a total of 1206 mg EPA and 609 mg DHA
will be administered daily. The placebo capsules have been
formulated to contain 320 mg of olive oil and 9.9 mg of
omega-3 fatty acids. Trace amounts of semi-deodorized
fish oil are added to the control oil so that its smell is not
perceivably different from that of the active oil.
Adherence to the regimens will be checked by clinical
research coordinators. Whole blood samples (7 ml) col-
lected with ethylene-diamine tetraacetic acid will be taken
at baseline, at 12 weeks’ follow-up, and at 1 month after
childbirth and omega-3 PUFAs will be determined as de-
scribed previously [34]. Briefly, erythrocytes will be
washed two time with saline and stored at−80 °C until
analysis. The method of Bligh and Dyer [35] will be used
to extract total lipids, and total phospholipid fractions will
be separated by thin-layer chromatography and trans-
methylated with by treatment with a mixture of HCl and
methanol. Next, fatty acid composition will be analyzed by
gas chromatography (GC-2014 Shimadzu Corporation,
Kyoto, Japan) controlled with GC-solution version 2.3
(Shimadzu Corporation, Kyoto, Japan) and equipped with
a DB-225 capillary column (length, 30 m; internal diam-
eter, 0.25 mm; film 0.25 μm; J&M Scientific, Folsom, CA).
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Assessment
The assessment schedule from baseline to 1 month after
childbirth is shown in Table 1.
Outcome measures
Primary outcome
The primary outcome is total score on the 17-item
Hamilton Rating Scale for Depression (HAMD) [36, 37] at
12 weeks after the start of the intervention. HAMD is a
widely used structural interview for assessment of depres-
sive symptoms and has been used during pregnancy and
in the postpartum period [26, 28, 38]. Trained psychia-
trists, psychologists, or nurses will conduct the structured
interviews for the evaluation. To assess inter-rater reliabil-
ity, 3 well-trained raters in Japan and 2 well-trained raters
in Taiwan have independently assessed the same person
acting as a patient in a video. The original video was made
in Japanese and then translated into Chinese for the raters
in Taiwan. The maximum variance in scores among the 5
raters from the expert gold standard score was satisfactory
for all the HAMD items. The intraclass correlation coeffi-
cient for the total HAMD score among the 5 raters was
0.967 (95 % confidence interval, 0.934–0.986).
Table 1 Outcome measures and assessments
Baseline 12 weeks 1 month after childbirth
Primary outcome
HAMD + + +
Secondary outcome
MINI + + +
EPDS + + +
BDI-II + + +
Plasma + + +




Erythrocyte + + +
Adverse effects + +
HAMD hamilton rating scale for depression (HAMD), MINI mini international
neuropsychiatric interview, EPDS Edinburgh postnatal depression scale, BDI-II
beck depression inventory-II
Eligible pregnant women (12-24 weeks gestation)
Refuse
Omega-3 fatty acids









4 weeks after childbirth
(n=)
4 weeks after childbirth
(n=)
Placebo
MDD (+)                MDD (-) 
12 weeks follow-up
(n=)
Fig. 1 Flow diagram of the study. EPDS: Edinburgh Postnatal Depression Scale; MDD: major depressive disorders
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Secondary outcomes
The secondary outcomes are:
 Total HAMD score at 4 weeks after childbirth
 Major depressive disorder (MDD) as determined by
the depression module of the Mini International
Neuropsychiatric Interview (MINI) [39] at 12 weeks
after starting the intervention and at 4 weeks after
childbirth-MINI is a concise structural interview for
the major Axis I psychiatric disorders described in the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition and the International Classification of
Diseases and Related Health Problems, Tenth Revision
 Total scores on the EPDS [40] at 12 weeks after
starting the intervention and at 4 weeks after
childbirth-EPDS is a widely used 10-item self-report
scale to assess the severity of perinatal depressive
symptoms in the past week; EPDS scores > 9 may
indicate the presence of MDD [41]
 Beck Depression Inventory II (BDI-II) [42] at
12 weeks after starting the intervention and at
4 weeks after childbirth-BDI-II is a widely used
21-item self-report scale to measure the severity of
depressive symptoms in the past 2 weeks [42]; it was
not designed to perinatal mood specifically but has
been used during pregnancy and in the postpartum
period [28, 43]
 Biomarkers levels at baseline, 12 weeks’ follow-up,
and 1 month after childbirth for
– Omega-3 fatty acids concentrations in erythrocytes
– Brain-derived neurotrophic factor (BDNF) in serum
– Estrogen in plasma
– Oxytocin in plasma
– Progesterone in plasma
– Human chorionic gonadotropin in plasma
– Phospholipase A2 in plasma
For the measurement of biomarkers, plasma and
serum will be drawn at baseline, at 12 weeks’ follow-up,
and at 1 month after childbirth. Samples will be stored
in separate freezers at−80 °C until analysis. All samples
will be analyzed on the same day and under the same
conditions by a biochemist blinded to the severity of de-
pressive symptoms and participants’ diagnostic status.
Other outcomes
Standard obstetric outcomes will be analyzed: gestational
age, gestational diabetes mellitus, gestational hyperten-
sion or preeclampsia, induced labor, estimated blood
loss, cesarean section, operative vaginal delivery, birth-
weight, 1-min and 5-min Apgar scores, and neonatal
intensive care unit admission. Data will be collected on
discontinuation of the allocated interventions.
Participant protection and reporting of adverse events
We define an adverse event as any unwanted or unin-
tended sign, symptom, or disease observed in the trial
participants, whether or not it is caused by study inter-
vention. Safety issues will be monitored by interview,
telephone, or email. Researchers and clinical research
coordinators will record and evaluate any suspected ad-
verse events. The follow criteria will guide evaluation of
the severity of adverse [34].
1) Mild: Some symptoms or signs observed. Treatment
is not required for the participant to continue in the
trial.
2) Moderate: Some symptoms or signs observed. The
participant may reduce the dose of test capsules or
receive treatment such as additional drugs to
continue the trial.
3) Severe: Clinical symptoms are severe enough to
interfere with daily activities. Discontinuation of test
capsules may be necessary.
The following are always regarded as serious adverse
events, regardless of test dosage.
1) An event that results in death
2) A life-threatening event
3) An event that requires hospitalization (or extends an
existing hospitalization period) in order to provide
treatment
4) An event that results in a permanent or prominent
disorder or a failure in body function
5) An event that results in a subsequent congenital
anomaly or deficiency
6) Other events considered medically significant
Any serious adverse event will be reported to and
assessed by the Data and Safety Monitoring Board as
soon as possible. The ethics committee will also receive
the report. Other adverse events will be reported and
evaluated regularly. Information on concomitant drug
use and reason for use will also be reported.
Estimation of sample size
The expected difference in total HAMD score between
the two arms at 12 weeks’ follow-up is set at 4.7 accord-
ing to a previous study [28]. It is expected that 12 % of
participants will discontinue the test capsules or drop
out of the trial. Given an α level of 0.05 (two-tailed), a β
level of 0.10, and standard deviation of 5, the desired
number of participants will be 28 in each arm and 56 in
total. Because a previous study suggested that seafood
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consumption varied across countries [33] and this may
have a major effect on the efficacy of omega-3 PUFAs,
56 participants will be recruited at each site in Japan and
Taiwan. Thus, the total number of participants will be
112. However, it is possible that enrollment will be
halted before reaching this target if significant financial
or logistical factors arise, or that number of cases at one
of the sites may exceed the target number depending on
the accumulation of cases at the other site.
Statistical analysis
Primary analysis
Primary analysis will be conducted according to the
intention-to-treat principle. Mean score differences,
95 % confidence intervals, and P values will be calcu-
lated using analysis of covariance in order to examine
whether participants receiving omega-3 PUFAs supple-
mentation score on average 4.7 points lower on the
HAMD at 12 weeks’ follow-up than participants receiv-
ing placebo. Two-tailed tests will be used, with the α
level set at 5 %. The assignment remains masked, but
any background factors that may predict primary out-
come will be entered as covariates if such factors are
found.
Exploratory analysis
We will conduct exploratory analysis of secondary out-
comes and sub-groups and therefore multiplicity will
not be controlled. A mixed effect model with repeated
measures will be evaluated by regression. The validity of
the findings will be examined through sensitivity ana-
lysis, including per protocol analysis and analysis of the
method used to impute missing variables.
Ethical considerations
This study protects the rights and welfare of participants
in the spirit of ethical guidelines outlined under the Dec-
laration of Helsinki. Informed consent to participate in
the study will be obtained from all participants. Personal
information about potential and enrolled participants
will be strictly secured to avoid external leaks before,
during, and after the trial. No special compensation will
be paid in the event of health damage directly related to
the research. The research plan was deliberated on and
approved by the following ethics committees: Tokyo
Medical University, Japan, 26 June 2013; and China
Medical University, Taiwan, 6 December 2013. If the
protocol needs to be changed for any reason, the princi-
pal investigators will communicate this with the institu-
tional review boards.
Data and safety monitoring
The data manager will use a premade template to create
a report to be sent to the principal investigator and the
Data and Safety Monitoring Board once every 6–12
months. The members of the Data and Safety Monitoring
Board are Professor Koichiro Watanabe (psychopharma-
cology), Dr. Katsumi Ikeshita (clinical psychiatrist), and
Dr. Tomohiro Nakao (psychotherapy), who are profes-
sionals with clinical trial experience with no involvement
in the trial. The monitoring report includes the following.
1) Progress of the study and case registration
2) Psychiatric evaluation status and any relevant issues
3) Any adverse events
4) Discussion of other relevant issues
Discontinuing intervention
Intervention will be discontinued if the participant does
not wish to continue taking the trial substance or pla-
cebo, or if continuing the intervention would be difficult
because medically required concomitant medication may
be affected by the trial substance. Subsequent evalua-
tions and follow-up will proceed as designed.
Presentation of the trial results
The findings of the trial will be presented in medical
journals and at academic conferences. If particularly
noteworthy results are obtain or the study is accepted by
an influential academic publication, an application for a
press release will be made. The principal investigators
are, in general, listed as corresponding authors. The
order of presentation of the first author and co-authors
will be determined according to their intellectual contri-
butions. Individuals who join the study after its approval
and work toward implementing and conducting the
study may obtain authorship pending approval by the
principal investigators.
Discussion
The findings of the SYNCHRO study are expected to in-
fluence decisions on the clinical care of pregnant women
with depressive symptoms. The strengths of the study
include its double-blind, placebo-controlled design, its
multicenter, multi-country collaboration, and its evalu-
ation of an EPA-rich supplement.
Maternal depression can have a significant harmful in-
fluence on both mothers and children. Due to the possi-
bility of adverse effects of antidepressants, omega-3
PUFAs may provide a safe alternative for pregnant
women with depressive symptoms. So far, only 2 RCTs
have examined the efficacy of omega-3 PUFAs with a
high ratio of EPA for depression in pregnancy [28, 43];
one of which recruited pregnant women without current
depression but with a history of depression [43]. In
addition, the result of one study on omega-3 PUFAs
conducted in one country may not be able to be applic-
able to other countries due to differences in fish
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consumption [33]. The SYNCHRO study should provide
evidence for two different populations in Asia and con-
tribute to promoting mental health of large numbers of
mothers and children.
Trial status
This randomized trial is now enrolling participants and
conducting follow-up.
Additional file
Additional file 1: SPIRIT Checklist. (DOC 124 kb)
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